<div class="headers"><div>Figure 4. Least squares (LS) mean differences between roflumilast and placebo in (A) pre- and (B) postbronchodilator FEV1 in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting β2-agonist.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 4. Least squares (LS) mean differences between roflumilast and placebo in (A) pre- and (B) postbronchodilator FEV1 in the ITT population and subpopulations. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting β2-agonist.</p></td>
</tr>
</tbody>
</table>
